BioAge Labs (BIOA) Change in Receivables (2025 - 2026)
BioAge Labs' (BIOA) quarterly Change in Receivables came in at -$84000.0 in Q2 2026, down 134.71% year-over-year from $242000.0 in Q2 2025, and down 40.0% quarter-over-quarter from -$60000.0 in Q1 2026.
Powered by 
Analysis
BioAge Labs (BIOA) Change in Receivables (2025 - 2026) Analysis & Trends
BioAge Labs has disclosed Change in Receivables across 2 years of filings, most recently posting -$84000.0 for Q2 2026.
- In Q2 2026, Change in Receivables fell 134.71% year-over-year to -$84000.0; the TTM figure through Jun 2026 stood at $22000.0 (down 96.35% YoY), while the FY2025 annual figure was $769000.0, changed N/A from the prior year.
- Change in Receivables came in at -$84000.0 for Q2 2026 at BioAge Labs, down from -$60000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $361000.0 in Q1 2025 to a low of -$88000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 1.09 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 333.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 140.20 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 838.50 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -53.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 269.40 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 37.16 Mn |
| 10 | BioAge Labs | 439.00 Mn | 439.00 Mn | -14.23 Mn | -84,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -84,000.00 |
| Mar 31, 2026 | -60,000.00 |
| Dec 31, 2025 | 254,000.00 |
| Sep 30, 2025 | -88,000.00 |
| Jun 30, 2025 | 242,000.00 |
| Mar 31, 2025 | 361,000.00 |